Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
File(s)
Author(s)
Califano, R
Greystoke, A
Lal, R
Thompson, J
Popat, S
Type
Journal Article
Abstract
Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2–7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a next generation ALK inhibitor (ALKi), approved by the European Medicines Agency in 2015. In the first‐in‐human, phase I study, ceritinib demonstrated rapid and durable responses in ALK patients previously treated with a different ALKi and in those who were ALKi‐naive. As ceritinib is starting to be used routinely for the treatment of patients with ALK+ NSCLC, experience is growing with regard to ideal therapy management. In this review we provide a brief background to the development of ceritinib. The optimal treatment management and adverse events associated with ceritinib in clinical trials and in clinical practice are then discussed in detail, and where applicable, an expert consensus on specific recommendations are made. In clinical trials, the most common adverse events related to ceritinib are nausea, vomiting, and diarrhea. However, the majority of these are mild and, in the opinion of the authors, can be effectively managed with dose modifications. Based on clinical data, ceritinib has demonstrated efficacy as a first-line therapy and in patients who have relapsed on crizotinib, including those with brain metastases at baseline. Unfortunately, at some point, all patients experience progressive disease, with the central nervous system being a common site of metastases. Recommendations are made for continuing treatment beyond disease progression as long as a clinical benefit to patients is observed. Here, we review management of ceritinib treatment and adverse events and make recommendations on optimal management of patients.
Date Issued
2017-06-09
Date Acceptance
2017-06-08
Citation
LUNG CANCER, 2017, 111, pp.51-58
ISSN
0169-5002
Publisher
ELSEVIER IRELAND LTD
Start Page
51
End Page
58
Journal / Book Title
LUNG CANCER
Volume
111
Copyright Statement
© 2017 Published by Elsevier Ireland Ltd. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411302900009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Respiratory System
Ceritinib
Anaplastic lymphoma kinase
Non-small cell lung cancer
Therapy management
Safety profile
INHIBITOR CERITINIB
KINASE INHIBITOR
CLINICAL IMPACT
CRIZOTINIB
CHEMOTHERAPY
RESISTANCE
PROGRESSION
SURVIVAL
NSCLC
1112 Oncology And Carcinogenesis
1103 Clinical Sciences
Oncology & Carcinogenesis
Publication Status
Published